Case Study 2 — How a Drug Class Shrinks Without a Villain
The story nobody writes
There is a well-worn narrative about medicines that lose their place. It goes: a drug is approved on thin or manipulated evidence; the manufacturer knows more than it says; harm accumulates; a journalist or a whistleblower or a lawsuit forces the truth out; a regulator acts late; there is a reckoning. Some version of that story is true often enough to matter, and the cases where it is true deserve every bit of the attention they get.
But it is not the only way a treatment loses ground, and it is not even the most common way. The most common way is much duller: the evidence base gets better, and the drug does not look as good in the better evidence as it did in the worse evidence. No villain. No suppression. No reckoning. Just a slow, unglamorous revision, distributed across a couple of decades and a dozen journals, ending with a drug that used to be everywhere quietly occupying a narrower niche.
Calcitonin is the clearest example of that process in this book, and it is worth studying precisely because it is undramatic.
The hypothesis, and why it was excellent
Calcitonin is a 32-amino-acid peptide hormone secreted by the thyroid C cells. Its classical physiological role is to lower blood calcium, chiefly by inhibiting osteoclasts — the cells that resorb bone. In the standard endocrine schematic it is drawn as parathyroid hormone's counterweight: PTH raises calcium, calcitonin lowers it.
From there, the therapeutic inference practically writes itself:
- Osteoporosis is a disease of excessive bone resorption.
- Calcitonin inhibits bone resorption.
- Therefore calcitonin should reduce bone loss, and therefore fractures, in osteoporosis.
That is a good argument. It is mechanistically sound at every step. It is the kind of reasoning that has produced many genuinely useful drugs, and anyone who tells you it is obviously naive is benefiting from hindsight they did not earn.
The therapeutic agent that emerged was usually salmon calcitonin rather than the human sequence, because salmon calcitonin is substantially more potent at the human calcitonin receptor — one of the odder facts in comparative endocrinology. It was available as an injection and, notably, as a nasal spray, which made it one of the earlier successful non-injectable peptide formulations and a genuine delivery achievement. Calcitonin was used for postmenopausal osteoporosis, for hypercalcemia of malignancy, and for Paget's disease of bone. It was a familiar prescription.
What happened, in three unrelated strands
Strand one: the competition got much better
Bisphosphonates arrived, became inexpensive, went generic, and — decisively — accumulated large randomized trials with fracture as the primary endpoint rather than bone density as a surrogate. Later, denosumab (a monoclonal antibody, not a peptide) and the anabolic agents from §29.2 added further options with their own fracture data.
This strand deserves emphasis because it is the one people find least satisfying. A drug does not have to be disproven to lose its place. It only has to be outperformed. In a therapeutic area with several well-evidenced choices, the agent whose evidence base is weakest gets used less, whatever its absolute merits. That is not injustice. It is what a functioning field does with limited prescribing attention.
Strand two: the fracture evidence never got strong
Calcitonin does things that are easy to measure. It inhibits osteoclast activity. It moves bone turnover markers. It has an analgesic effect in acute vertebral fracture that some clinicians still value and defend.
What it never convincingly demonstrated was a robust reduction in fracture risk on the scale the bisphosphonate trials showed.
The trial usually cited is the one known by the acronym PROOF — Prevent Recurrence Of Osteoporotic Fractures — a multi-year randomized placebo-controlled study of nasal salmon calcitonin with several active dose arms. It reported a statistically significant reduction in new vertebral fractures in one dose arm relative to placebo.
That result did not settle the question, for a reason that generalizes well beyond calcitonin.
The arms did not line up. The middle dose separated from placebo; the highest dose tested did not, or did so less clearly. A real drug effect usually shows a dose-response relationship — more drug, more effect, up to a plateau or a toxicity ceiling. When a middle dose beats placebo and a higher one does not, three explanations are on the table:
- There is an unusual biological reason. Possible, but it has to be argued, not assumed.
- Differential dropout across arms distorted the comparison. PROOF had considerable attrition over its duration, which was widely discussed.
- The positive arm is a chance finding among several comparisons.
Any of those could be right. Distinguishing among them requires replication at scale, and replication at scale never came — partly because by the time the question was pressing, the therapeutic area had better options and less reason to fund an expensive confirmatory trial of a fading agent.
Strand three: regulators revisited the question
In the early 2010s, regulators on both sides of the Atlantic reviewed calcitonin. A European review concluded that the benefit-risk balance did not favor its use for osteoporosis, citing a small increase in cancer diagnoses observed with long-term use across pooled trial data, and restricted the approved uses accordingly. In the United States, an advisory committee reviewing the osteoporosis indication expressed substantial doubt about it. Details differ by jurisdiction and by formulation, and the status of individual products has continued to shift. The direction of travel has been consistent.
The result: contraction, not collapse
Put the three strands together and you get something that needs a more precise word than "failure."
Calcitonin was not withdrawn. It remains available. It retains a role in hypercalcemia, in Paget's disease, and in acute vertebral fracture pain. What it lost is the broad osteoporosis role it once occupied — and it lost it for the most respectable reason a treatment can lose ground: more was learned, and what was learned did not support the original enthusiasm at the original scale.
That is worth saying plainly, because the rating this book issues can be misread. "Calcitonin for osteoporotic fracture reduction: ⚠️ → ❌" is a statement about that claim. It says nothing about hypercalcemia, nothing about Paget's disease, nothing about fracture pain, and nothing about whether the molecule does anything at all. One molecule, many claims, many ratings — the sixth rule of the system, doing real work.
Why this belongs in a book about peptides
Because the most persistent argument you will meet in the peptide gray market is that mainstream medicine does not revise itself. That approved drugs stay approved because of money. That inconvenient findings get buried. That the system is not really an evidence system at all.
Calcitonin sits in plain sight as a counterexample, and it is a better one than a scandal would be. A scandal proves the system can be forced to correct under external pressure. Calcitonin shows it correcting without external pressure — without a journalist, without a lawsuit, without anyone gaining reputationally from the correction. Researchers ran better trials. Reviewers read them carefully. Regulators reweighed. Prescribers moved. It took two decades and produced no headlines.
And that is exactly the mechanism the unregulated peptide market does not have. A compound sold outside the approval system has no process by which a claim about it can lose. There is no confirmatory trial that might fail, no regulator who might reweigh, no competitor with better fracture data to be outperformed by. The claim persists as long as demand persists. The absence of a mechanism for losing is not a neutral feature of that market — it is the central structural difference between it and the one that produced calcitonin's honest, boring, entirely unremarkable retreat.
Discussion questions
1. Reconstruct the mechanistic argument for calcitonin in osteoporosis, step by step. Identify precisely which step turned out to be the weak one, and explain why that step could not have been identified in advance from the mechanism alone.
2. Three separate strands contributed to calcitonin's contraction. Which strand would have been sufficient on its own? Which would have been insufficient? Defend your answer.
3. In PROOF, one dose arm separated from placebo and a higher one did not. Describe the three explanations for that pattern given above, and design a study that could distinguish among them. Then explain why that study was never run, and whether its absence is a failure of the system or a reasonable allocation of research funding.
4. This case study claims that "a drug does not have to be disproven to lose its place; it only has to be outperformed." Is that a healthy property of a therapeutic field, or a way for genuinely useful agents to be lost? Argue both sides, then state your own position.
5. The chapter rates calcitonin for fracture reduction ⚠️ → ❌ while insisting the rating does not travel to its other uses. Write out the rating you would issue for calcitonin in acute vertebral fracture pain, in the four-line format. Then explain why a reader who saw only a single molecule-level rating would be misled — and say in which direction.
6. The closing argument is that the unregulated peptide market lacks "a mechanism for a claim to lose." Test that argument. Pick a specific gray-market peptide claim and describe what would have to exist — institutionally, financially, and evidentially — for that claim to be capable of losing. Then say whether any of those things could plausibly come into being, and what would have to change for them to.